Sartorius Stedim Biotech SA
DIM: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€721.00 | Zqbgc | Tnwdvjfwl |
Wide-Moat Sartorius Stedim Delivers Solid Growth Despite Growing Challenges; Maintaining FVE
Wide-moat Sartorius Stedim (Sartorius Ag's bioprocess subsidiary) delivered solid third-quarter results, but weak order trends, economic challenges, and an increase in the company's cost base suggest a deceleration in growth is coming, which is in line with our long-term forecast. We may adjust our short-term operating expectations slightly, but at first glance, we will likely maintain our EUR 290 fair value estimate.